Study of MC4R Agonist for Bardet-Biedl Syndrome and Genetic Obesity
Treatments studied
Part of Brain & nervous system, Eyes & vision, Genetic & congenital clinical trials.
This trial tests a drug called setmelanotide for people with Bardet-Biedl Syndrome (a rare genetic condition) or other severe genetic obesity. It looks at how well the drug works in real-world settings, not just in a lab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Bardet-Biedl Syndrome or another severe form of genetic obesity.
- You have had genetic testing that found a change in a gene related to obesity.
- You are old enough to take setmelanotide (check with your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects health and genetic information from people with Bardet-Biedl syndrome. It may help researchers better understand the condition and improve future care by building a clear group of eligible patients.
This study follows people with Bardet-Biedl syndrome (BBS) or Alström syndrome (ALMS) to spot early vision, metabolic (body chemistry/energy), and kidney problems. You may be asked to have clinical checks over time to help researchers better understand how these complications develop.
This report describes a rare case of Bardet-Biedl syndrome in a teenager from Syria. The trial is open to anyone, so it may help doctors learn more about this condition.
This trial looks at whether drugs already approved for other conditions might help people with Leigh syndrome, a rare mitochondrial disorder. Researchers will study cells made from your skin to see how these drugs work.
This study tests a new medicine called PF-08653945 to see how it enters the blood in adults who are overweight or have obesity. The results will help doctors understand how the medicine works in the body.
This trial tests a medicine called atomoxetine (Strattera) to help people with a specific genetic form of obesity lose weight. It may be an option if you have a change in the MC4R gene and have not used certain other medications recently.
Hear when a new Bardet Biedl Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.